Azoles are widely used in the treatment of fungal infections. They act by competitive inhibition of lanosterol 14a-demethylase (P45014DM, CYP51), the key enzyme in sterol biosynthesis, which results in depletion of ergosterol and accumulation of lanosterol and other 14-methyl sterols ultimately leading to the growth inhibition of fungal cells.1) Inhibition of the ergosterol biosynthetic pathway in fungi has thus attracted intense interests in the application of such antifungal compounds. However, it was found in the past two decades that azole resistance often develops prolonged use of oral imidazole and triazole, or different forms of immunodeficiency in fungal infection patients.2) Furthermore, cross inhibition of CYP51 in different species also causes undesirable side effects.3) It is, therefore, of increasingly interest to develop novel antifungal agents with more selective antifungal activity, higher efficiency, broader pectrum, and lower toxicity.Azole antifungal agents inhibit the CYP51 by a mechanism in which the heterocyclic nitrogen atom (N-3 of imidazole and N-4 of triazole) binds to the heme iron atom in the binding site of the enzyme. Because all the fungal CYP51 proteins that had been characterized were membrane-bound and difficult to solve their crystal structures, the study of the interaction between azoles and fungal CYP51 can only be done by methods of molecular modeling. Several three-dimensional (3D) models of CYP51 and their interaction with azole antifungal agents has been reported. Ji et al. 3,4) built a homologous 3D model of CYP51 from C. albicans based on the crystal coordinates of all four known prokaryotic P450s. With this model they found that the halogenated phenyl group of azole inhibitors is deep in the hydrophobic binding cleft and the long side chains of some inhibitors such as itraconazole and ketoconazole surpass the active site and interact with the residues in the substrate access channel. Another 3D molecular model constructed by Lewis et al. 5) also showed that typical azole inhibitors were able to fit the putative active site of CYP51 by a combination of heme coordination, hydrogen bonding, p-p stacking and hydrophobic interactions within the heme environment of the enzymes. Recently, modelling data of Li et al. 6) suggest that the long chain of posaconazole and itraconazole occupies a specific channel within CYP51 and that this additional interaction serves to stabilize the binding of these azoles to the mutated CYP51 proteins. Models generated by Fukuoka et al. 7) predicted that voriconazole was a more potent inhibitor than fluconazole because the additional methyl group of voriconazole resulted in stronger hydrophobic interaction with the aromatic amino acids in the substrate binding site and filled the site more extensively.In our studies, the 3D model of CYP51 from Candida albicans (CACYP51) was constructed.3) In addition, the binding mode of the substrate with fungal CYP51 was also investigated.3) In order to search more potent azoles antifungal agents and desi...